FY2026 Earnings Forecast for Arvinas Issued By HC Wainwright

Arvinas, Inc. (NASDAQ:ARVN) – Equities research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Arvinas in a report released on Tuesday, November 3rd. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of $0.00 per share for the year. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Arvinas’ current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Arvinas’ Q4 2026 earnings at ($0.88) EPS, Q1 2027 earnings at ($0.55) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.63) EPS, Q4 2027 earnings at ($0.67) EPS, FY2027 earnings at ($2.44) EPS, FY2028 earnings at ($2.70) EPS, FY2029 earnings at ($1.74) EPS and FY2030 earnings at ($0.72) EPS.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.10. Arvinas had a negative return on equity of 2.06% and a negative net margin of 3.45%. The business had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $12.39 million. During the same quarter in the prior year, the business earned ($0.48) EPS. The firm’s revenue for the quarter was down 98.8% on a year-over-year basis.

A number of other research firms have also recently issued reports on ARVN. Morgan Stanley set a $10.00 target price on shares of Arvinas in a research note on Monday, August 10th. Weiss Ratings cut shares of Arvinas from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, October 23rd. Wells Fargo & Company cut shares of Arvinas from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $15.00 to $11.00 in a report on Tuesday, August 4th. Wedbush raised their price objective on shares of Arvinas from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Finally, Zacks Research upgraded Arvinas from a “hold” rating to a “strong-buy” rating in a report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $15.18.

Arvinas Price Performance

NASDAQ:ARVN opened at $7.42 on Thursday. Arvinas has a one year low of $6.74 and a one year high of $14.51. The company has a market cap of $478.75 million, a P/E ratio of -30.92 and a beta of 1.81. The firm’s fifty day moving average price is $7.98 and its two-hundred day moving average price is $9.63.

Institutional Investors Weigh In On Arvinas

Institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Arvinas in the third quarter valued at approximately $26,000. Integrated Wealth Concepts LLC acquired a new stake in Arvinas during the second quarter worth approximately $48,000. Pinnacle Wealth Planning Services Inc. acquired a new stake in Arvinas during the third quarter worth approximately $45,000. Quantbot Technologies LP acquired a new stake in Arvinas during the second quarter worth approximately $85,000. Finally, Corient Private Wealth LP bought a new position in Arvinas during the 2nd quarter worth $95,000. Institutional investors own 95.19% of the company’s stock.

Key Headlines Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, implying about 75% upside from the cited $7.42 share price. Arvinas Stock Picked Up by Analysts at HC Wainwright
• Neutral Sentiment: Arvinas plans to present preliminary Phase 1 data for ARV-393 at the 2026 American Society of Hematology meeting. The presentation could provide a clinical catalyst, though the report does not disclose results yet. Arvinas to Present Preliminary ARV-393 Clinical Data
• Negative Sentiment: Recent quarterly results showed revenue of just $0.5 million, far below the $12.39 million analyst estimate and down 98.8% year over year. The $0.82-per-share loss was better than the consensus loss estimate, but wider than the year-ago loss. Arvinas Reports Third Quarter 2026 Results
• Negative Sentiment: HC Wainwright’s estimates anticipate losses in 2027–2030, including a $2.44-per-share loss in 2027, underscoring the company’s ongoing path to profitability risk despite the bullish rating.

Arvinas Company Profile

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company’s proprietary PROTAC® protein degrader platform is designed to direct the body’s natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.